AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
(Full text of statement. Contact details below.)
MUNICH, Aug. 31 /PRNewswire-AsiaNet/ --
The established antihypertensive agent TEVETEN(R) (eprosartan) has now been shown to offer effective protection against cerebrovascular and cardiovascular events in hypertensive patients with a previous stroke, over and above that offered by blood pressure reduction.
Initial results from the landmark MOSES(1) study, presented by Professor Joachim Schrader at the XXVI Congress of the European Society of Cardiology in Munich, showed that blood pressure was equally well controlled when hypertensive patients with a history of stroke were treated with either TEVETEN(R)-based or nitrendipine-based therapies. However, there was a significant reduction of 20% in the primary endpoint (total mortality and total cardiovascular and cerebrovascular events) in the TEVETEN(R) group. In addition, there was a significant reduction of 25% in the recurrence of stroke and associated disease (transient ischaemic attack (TIA) and prolonged reversible neurological deficit (PRIND)), and a significant reduction of 30% in first-time cardiovascular events in patients treated with TEVETEN(R).
TEVETEN(R) is a member of the class of drugs known as angiotensin-II receptor antagonists, which target the renin-angiotensin-aldosterone system. Other drugs from this class have previously demonstrated cardio- and cerebroprotective effects in patients at risk of stroke. However, earlier studies focused on patients who, although at risk, have not yet had a stroke. These studies helped to establish the value of antihypertensive treatment in primary stroke prevention, but until now there were few data on the effectiveness of these drugs in preventing recurrent stroke.
MOSES is the first study to specifically compare the outcomes of alternative antihypertensive treatment in patients with a history of stroke. The calcium channel blocker nitrendipine was chosen as the comparator agent because of its success in the ...